Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Continuous tube better than intermittent feeding for haemorrhagic stroke patients

24 Oct 2020

Although continuous tube feeding is effective in enhancing the tolerance of enteral nutrition, a recent study has found not enough evidence supporting its advantage in calorie intake in patients with haemorrhagic stroke.

The investigators sought to examine the effects of intermittent as opposed to continuous tube feeding on its intolerance performance and efficiency of calorie intake in a convenience sample selected from January 2018 to January 2019 in the Neurosurgery Department of West China Hospital, Sichuan Province. Participants were randomized to receive either intermittent or continuous tube feeding, fed four times or 24 hours a day using electric feeding pump, respectively. The incidences of the intolerance and calorie intake were then recorded and analysed.

Seventy patients participated in this randomized controlled trial: 40 in the intermittent group and 38 in the continuous tube feeding group. Participants in the latter had significantly lower incidence of diarrhoea compared with those in the former (7.9 percent vs 37.5 percent; p=0.002).

The continuous tube feeding group also showed significantly lower total intolerance than the intermittent group (63.2 percent vs 85 percent; p=0.027), but no significant between-group difference was found in calorie intake during the first 3 days (2595.4±394.5 vs 2317.8±645.1 kcal; p=0.099). There was also no significant difference seen in total calorie intake between the two groups (6265.6±1261.3 vs 6429.4±1452.4 kcal; p=0.597).

An earlier study reporting the pros and cons of continuous and intermittent feeding reported that the latter had not been shown to increase glucose variability or gastrointestinal intolerance, making the former the preferred method. [Curr Opin Crit Care 2018;24:256-261]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.